CClinicalTrials.gg
Status unknownNCT0119249010-053Updated Jun 16, 2011

Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices

An interventional study of Lidocaine and Lubricant in Contraception, sponsored by University of Tennessee. Status unknown at 1 site in United States. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-06-16.

Sponsored by University of Tennessee · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jun 2011), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Sex
Female
01

Study summary

The hypothesis of this study is that topical cervical and intra-cervical lidocaine will decrease pain associated with the insertion of a Mirena® (levonorgestrel intrauterine device).

  1. Primary Aim- Determine if topical lidocaine intra-cervically and on the cervix decreases the pain associated with insertion of a Mirena® (levonorgestrel intrauterine device).
Read the detailed description

There have been multiple studies performed to determine a medication that will decrease the pain associated with intrauterine device insertion. These studies have tested the use of misoprostol as well as NSAIDS to determine if these decrease the pain associated with insertion. There has also been one small, poorly performed, study that tested the use of intracervical topical lidocaine prior to IUD insertion. Misoprostol and NSAIDS were found to be non-efficacious in decreasing pain. Topical lidocaine was shown to be effective, however, secondary to this being a poorly performed study, additional studies are needed. This study is to determine if topical lidocaine does indeed decrease the pain associated with insertion of the Mirena® (levonorgestrel intrauterine device).

This is a double blinded experimental study to determine whether or not topical lidocaine gel applied to the cervix and intra-cervically decreases pain associated with insertion of the Mirena® (levonorgestrel intrauterine device). Subjects will be randomized into two groups. One group will receive 2% lidocaine gel on the cervix and intra-cervically. The other group will receive a placebo, which will consist of KY being placed on the cervix and intra-cervically. After the Mirena® (levonorgestrel intrauterine device) is inserted, each subject's pain will be assessed by using a visual analog pain scale, and their response will be recorded on the information form. This pain scale will be assessed at the time of insertion, five minutes after insertion, and ten minutes after insertion. The only other study that researched the use of topical lidocaine prior to insertion of an IUD only recorded a pain scale at the time of insertion. Additional scores will be recorded at five and ten minutes to determine if pain is reduced in those time periods. These time periods have been chosen in order that all of this information can be recorded during a normal office visit. A visual analog pain scale is the scale included which measures pain on a scale of zero to ten with zero being no pain at all and ten being the worst pain of your life. This pain scale will be a scale ranging from zero to ten with faces depicting the amount of pain involved for each score. Since there will be different physicians placing the intrauterine devices, there will be a protocol on how to perform the insertion in an attempt to make all insertions as uniform as possible. A copy of this protocol has been included.

02

Conditions studied

  • Contraception
03

In context

Lead sponsor

University of Tennessee is the lead sponsor of 139 studies on the registry; 21 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Any subject receiving a Mirena® (levonorgestrel intrauterine device) for standard indications.
  2. Subjects who received nonsteroidal anti-inflammatory drugs (NSAIDS) will not be excluded.

Exclusion criteria

Exclusion Criteria:

  1. Subjects do not desire to be involved in the study
  2. Subjects who have taken narcotics.
  3. If the Mirena® (levonorgestrel intrauterine device) is not able to be successfully placed.
  4. If cervical dilation is required, these subjects will be placed in a separate subset and will be reported on separately.
  5. Subject has allergy to lidocaine.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Lidocaine Arm

    This arm will receive intracervical and cervical lidocaine prior to placement of a Mirena.

    Drug: Lidocaine

  • Placebo comparator
    Lubricant

    Subjects in this arm will receive KY gel intracervically and on the cervix prior to placement of a Mirena.

    Drug: Lubricant

Interventions

  • DrugLidocaine

    5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena

    Also known as: Mirena

  • DrugLubricant

    KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena

    Also known as: KY gel

06

What researchers measure

Primary outcomes

  1. Determine if topical lidocaine intra-cervically and on the cervix decreases the pain associated with insertion of a Mirena® (levonorgestrel intrauterine device).

    In order to analyze the data, pain scores will be stratified into three different categories. These categories will be as follows: visual analog scale (VAS) score of 0-2, VAS score of 2-4, VAS score of 5 and greater. This will allow an odds ratio to be calculated and the use of a Chi Square analysis.

    Time frame: 2-3yrs

07

Study locations

1 of 1 sites recruiting
  • University of Tennessee Chattanooga Department of Obstetrics and Gynecology
    Chattanooga, Tennessee 37403, United States
    • Ben Moore, MD · Contact · benatmc@hotmail.com · 423-778-2580
    • Brett Bryant, MD · Contact · brett_bryant@hotmail.com · 423-778-7515
    • Kirk Brody, MD · Principal investigator
    • Benjamin Moore, MD · Sub investigator
    • Joseph Bryant, MD · Sub investigator
    • David Barker, MD · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01192490
Lead sponsor
University of Tennessee
First posted
Sep 1, 2010
Start date
Aug 2010
Primary completion
Sep 2012 (estimated)
Completion
Dec 2012 (estimated)
Last update
Jun 16, 2011

Study contacts

Ben Moore, MD
Contact
benatmc@hotmail.com
423-778-7515
Brett Bryant, MD
Contact
bryant_brett@hotmail.com
423-778-7515
Kirk Brody, MD
principal investigator · University of Tennessee Chattanooga Department of Obstetrics and Gynecology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion